Novo Nordisk's stellar Wegovy-fuelled run of hiking sales guidance could be ending
By Maggie Fick LONDON (Reuters) - Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several times a year. But recent weak U.S. prescription data is leading some investors and analysts to …